Form 4: Supernus CEO Exercises Options, Sells Shares Under 10b5-1 Plan

Supernus Pharmaceuticals' President and CEO, Jack A. Khattar, exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 plan.

Summary

• Jack A. Khattar, President, CEO, and Director of Supernus Pharmaceuticals, Inc., engaged in transactions involving the company's common stock on September 8, 2025.
• Mr. Khattar exercised employee stock options to acquire 8,074 shares of common stock at an exercise price of $25.30 per share.
• Concurrently, he sold 6,322 shares of common stock at a weighted average price of $46.29 per share, with individual sales ranging from $46.00 to $46.40.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on November 14, 2024.
• Following these transactions, Mr. Khattar directly beneficially owns 1,111,983 shares of Supernus common stock and 162,500 employee stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, the transactions were pre-planned under a 10b5-1 plan, and the sale occurred at a significantly higher price than the option exercise price, indicating a profitable event for the executive. It's a routine compensation-related transaction rather than a signal of distress.

Positives

• The CEO exercised options, indicating a belief in the company's long-term value when the options were initially granted.
• The sale price of $46.29 is significantly higher than the exercise price of $25.30, indicating a profitable transaction for the CEO.
• Transactions were conducted under a pre-arranged 10b5-1 trading plan, which suggests planned, not opportunistic, selling and aligns with good corporate governance practices.

Negatives

• Insider selling, even if planned, can sometimes be perceived negatively by the market, though the volume here is not exceptionally large relative to total holdings.

Future Outlook

This Form 4 filing reports past insider transactions and does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Insider transactions like these are common across all industries, including pharmaceuticals. The exercise of options and subsequent sale of shares by a CEO under a 10b5-1 plan is a routine event for executive compensation and personal financial planning, and does not inherently signal specific industry trends or competitive positioning.

Comparison to Industry Standards

• Form 4 filings are standard regulatory disclosures for insider transactions across all publicly traded companies.
• The specific details of option exercise prices and sale prices are unique to the individual's compensation structure and the company's stock performance.
• The use of a 10b5-1 plan aligns with best practices for insider trading compliance, demonstrating a pre-planned approach to equity transactions, which is common among executives in the pharmaceutical sector and beyond.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO, while a reduction in direct holdings, was conducted under a 10b5-1 plan, which generally mitigates concerns about opportunistic selling. The CEO retains a significant number of shares and options, indicating continued alignment with shareholder interests.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• The reporting person will continue to report any future changes in beneficial ownership as required by Section 16(a) of the Securities Exchange Act of 1934.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where the CEO exercised stock options and sold a portion of the acquired shares under a pre-arranged 10b5-1 plan. While the sale of shares by an insider can sometimes raise questions, the pre-planned nature mitigates concerns about opportunistic selling. The CEO retains a substantial stake in the company. This transaction alone does not provide sufficient new information to warrant a change in investment thesis for Supernus Pharmaceuticals, hence a 'hold' recommendation is appropriate, pending further fundamental analysis of the company's operational and financial performance.

Keywords

Supernus Pharmaceuticals, SUPN, Insider Trading, Form 4, Stock Options, CEO, Jack A. Khattar, 10b5-1 Plan, Equity Transaction, Pharmaceuticals